Metabolic and vascular factors have been invoked in the pathogenesis of diabetic neuropathy but their interrelationships are poorly understood. Both aldose reductase inhibitors and vasodilators improve nerve conduction velocity, blood flow, and (Na',K+)-ATPase activity in the streptozotocin diabetic rat, implying a metabolic-vascular interaction. NADPH is an obligate cofactor for both aldose reductase and nitric oxide synthase such that activation of aldose reductase by hyperglycemia could limit nitric oxide synthesis by cofactor competition, producing vasoconstriction, ischemia, and slowing of nerve conduction. In accordance with this construct, N-nitro-L-arginine methyl ester, a competitive inhibitor of nitric oxide synthase reversed the increased nerve conduction velocity afforded by aldose reductase inhibitor treatment in the acutely diabetic rat without affecting the attendant correction of nerve sorbitol and myo-inositol. With prolonged administration, N-nitro-L-arginine methyl ester fully reproduced the nerve conduction slowing and (Na',K+)-ATPase impairment characteristic of diabetes. Thus the aldose reductase-inhibitor-sensitive component of conduction slowing and the reduced (Na+,K+)-ATPase activity in the diabetic rat may reflect in part impaired nitric oxide activity, thus comprising a dual metabolicischemic pathogenesis. (J. Clin. Invest. 1994. 94:853-859.)
Introduction
Both metabolic (1-3) and vascular (4-7) defects have been implicated in the pathogenesis of diabetic neuropathy, but the interrelationships among them are poorly understood. In the diabetic rat, metabolism of excess glucose to sorbitol by aldose reductase (AR2)' and then to fructose by sorbitol dehydrogenase (SDH) has been associated with reciprocal depletion of myoinositol (MI) and other intracellular organic osmolytes (8) , altered phosphoinositide metabolism, and reduced (Na+,K+)-ATPase activity in nerve; these metabolic derangements, alone or in concert, have been invoked in the aldose reductase inhibitor (ARI)-sensitive slowing of nerve conduction velocity (NCV) in acute experimental (1, 9) and (by analogy) human diabetes (2, 10) . Because AR2 and SDH are NADPH:NADP+ and NAD+:NADH coupled, respectively, glucose-induced flux through these enzymes is associated with increased oxidative stress (secondary to diminished NADPH-dependent reduction of glutathione) (11) and a putative state of "pseudohypoxia"
(manifested by a shift in the lactate/pyruvate ratio) (12) . Endoneurial blood flow is also diminished shortly after the induction of diabetes in the rat, and vasodilator treatment or pharmacologic adrenergic sympathectomy increases endoneurial blood flow and NCV, implicating neural ischemia as well in the early and reversible slowing of NCV (5) (6) (7) 13) . Moreover, ARI treatment, which restores nerve osmolyte levels (1) (2) (3) 8) and NCV (1, 2, 8, 13) , also corrects decreased endoneurial blood flow (13) and impaired "endothelium-dependent" aortic relaxation (thought to be nitric oxide-[NO]-mediated) in chronically streptozotocin-diabetic (STZ-D) rats (14) . Indeed several studies now suggest that microvascular disregulation in diabetes may primarily involve the "endothelial-dependent" NO-mediated component (15) (16) (17) (18) . Finally, NO synthase (NOS) inhibition reproduces the glucose-induced decrease (19) in (Na+,K+)-ATPase activity in isolated rabbit aortic rings in vitro (20) . These observations together provide the framework for a potential novel metabolic-vascular pathogenetic matrix for diabetic neuropathy involving AR2, NO, and (Na+,K+)-ATPase.
The present studies were therefore undertaken to identify a potential role for AR2-related defects in NO synthesis or action in the pathogenesis of the reduced NCV and/or nerve (Na+,K+)-ATPase activity in the STZ-D rat model. These studies assessed the ability of a specific NOS inhibitor, N-nitro-L-arginine methyl ester (L-NAME), an arginine analog that competes for the en- Data given as mean±SE. * P < 0.01 vs control and control + L-NAME. (ND) Nondiabetic control; (ND:L-NAME) nondiabetic L-NAME-treated; (D) diabetic; (D:L-NAME) diabetic L-NAME-treated; (D:ARI) diabetic ARI-treated; (D:L-NAME + ARI) diabetic L-NAME-plus ARI-treated.
zyme's substrate binding site (21) (22) (23) (24) , and effectively inhibits both constitutive and the inducible NOS (21) (22) (23) (24) , to block the salutary effect of ARI treatment on NCV in the STZ-D rat, and to reproduce the slowed NCV of STZ-D in nondiabetic rats. L-NAME was able to prevent the beneficial effects of an ARI on NCV despite correction of nerve sorbitol and MI levels. L-NAME also slowed NCV in nondiabetic rats, though only after prolonged administration, with an attendant reduction in (Na',K+)-ATPase activity. (26) . The proximal and distal latencies of the compound muscle action potentials, recorded via bipolar electrodes from the first interosseous muscle of the hindpaw, were measured from the stimulus artifact to the onset of the negative M-wave deflection, subtracted, and divided into the distance between the stimulating and recording electrodes giving a value for NCV in m/s.
Measurement of systolic blood pressure. Systolic blood pressure (SBP) was measured by the indirect tail-cuff technique (27) on days 0 and day 21 . Rats were prewarmed with a heating pad for 3 min before 10-20 measurements were taken 30 s apart with a Programmed Electrosphygmomanometer (model PE-300; Narco BioSystems, Austin, TX) precalibrated with a mercury manometer, and recorded on a model 7D polygraph (Grass Instrument Co., Quincy, MA). SBP was defined as the mean of the last five recordings. This method was previously validated by simultaneous intra-carotid recording (27) .
Measurement of sciatic nerve glucose, MI, sorbitol, and fructose. The left and right sciatic nerves were rapidly surgically exposed from the vertebral exit to the common peroneal bifurcation, excised, cleaned of adherent muscle and loose epineurial connective tissue, and immediately frozen in liquid nitrogen for subsequent determination of nerve osmolyte levels (25, 26, 28) . Sciatic nerve MI, sorbitol, and fructose were determined by gas chromatography of aldonitrile acetate derivatives of lyophilized aliquots of deproteinized homogenates (2.0 ml 5% wt/vol trichloroacetic acid) of sciatic nerve containing 10 jg a-D-methyl mannopyranoside as an internal standard (25, 26, 28) . A Varian 3700 gas-liquid chromatograph was equipped with a 30 m X 0.25 mm inner diameter SP-2100 fused silica capillary column with a 0.25 ,sm film thickness, a single flame ionization detector, a 8100 autosampler, and a Star Workstation Integrator (Varian Instruments, Sunnyvale, CA). The He carrier gas flow was 0.6 m/min with split ratio of 15:1, and the column temperature was held for 2 min at 175°C and increased at 3°C/ min to 270°C and held. Standard curves were generated daily, and recoveries routinely exceeded 95%.
(Na+K+)-ATPase assay. 
Results
Baseline body wts were similar in all the experimental groups (Table I) , but attained body wts were 21-29% lower in D vs ND groups, and unaffected by L-NAMiE or sorbinil. Untreated D and ND rats exhibited 14-16% increases in SBP after 21 d. As expected (21, 24, 27, 29) , L-NAME increased SBP vs relevant controls from 27% in ND to 44% in D:ARI rats, with none of the SBP differences among L-NAME groups attaining statistical significance (Fig. 1) . Effect of diabetes, ARI, and L-NAME on nerve glucose, fructose, sorbitol, and MI. Nerve glucose was increased 2.8-3.4-fold in D rats, with no significant differences among D groups (Table II) . Nerve fructose was increased 6.5-and 4.6-fold, respectively, in D and D:L-NAME rats vs their ND controls, and lowered by 60-62% (P < 0.01) by ARI (Table TI) . Nerve sorbitol was increased 6.5-and 6-fold, respectively, in D and D:L-NAME rats respectively and reduced by 50-69% (P < 0.01) by ARI (Table TI) . ARI corrected nerve MI in D rats to 94% of the ND level, and L-NAME had no effect on nerve osmolytes in D or ND rats (Table IT) . Effect of diabetes, ARI, 1% dietary MI, and L-NAME on NCV. 3 wk of L-NAME treatment produced a slight (7.5%) but statistically insignificant slowing of NCV in ND rats (Fig. 2 ) which was not augmented by a lOX higher L-NAME dose to correct for higher water intake in STZ-D rats (data not shown). Three wks of STZ-D slowed NCV by 24% (P < 0.01) (Fig.  2) . L-NAME slowed NCV no further in D rats (Fig. 2) . ARI increased NCV 18.8% (P < 0.01) in D rats to a level statistically indistinguishable from that of ND rats (Fig. 2) . Despite the fact that L-NAME had no effect on NCV in untreated D rats, L-NAME decreased NCV in ARI-treated D rats to a level indistinguishable from that of untreated D rats (Fig. 2) . In order to demonstrate that the effects of L-NAME on NCV in the ARI treated D animals were due to specific inhibition of NO synthesis the effects of the simultaneous addition of arginine (274 mM in drinking water) were examined in 10 animals. Arginine was found to preserve NCV at levels that were indistinguishable from the ND control animals (56.1+2.3 mIs) and prevent the hypertensive effect of L-NAME (SBP 121±5 mmHg at 3 wk). Dietary MI supplementation increased NCV in D rats given L-NAME to a level indistinguishable from that of the ND controls (55.6±1.8 m/s, n = 5), despite unabated hypertension (see panels B, Figs. 1 and 2 ). Thus, in contrast to its potent anti-ARI effect, L-NAME did not block the beneficial effect of dietary MI on NCV in D rats (9) .
Effects ofchronic (3 mos) L-NAME on NCV and nerve MI in ND rats. 3 mos of L-NAME treatment (ND:L-NAME-chronic) decreased NCV 17% (P < 0.01) to levels indistinguishable from rats with 3 mo of STZ-D (D-chronic) (Fig. 3) . The L-NAME-induced increase in SBP after 3 mos (165±3 mmHg) was not significantly different from that after 3 wk L-NAME treatment. Nerve MI levels in ND:L-NAME-chronic rats were 19% lower than in untreated ND rats, but this change was statistically insignificant. To assess the specificity of the effect of ARI on reduced NCV, NCV was measured in ND rats treated for 3 mos with L-NAME + ARI (n = 4). ARI plus L-NAME for 3 mos did not change either SBP or NCV compared with ND animals (n = 5) treated with L-NAME alone (data not shown).
Effects ofdiabetes and L-NAME on nerve (Na+,K+)-ATPase activity. To assess whether NOS inhibition diminished NCV through a (Na+,K+)-ATPase mechanism, ouabain-sensitive ATPase activity was measured in nerve homogenates from NDchronic, ND:L-NAME-chronic, and D-chronic rats. Ouabainsensitive ATPase activity was reduced by 34% (P < 0.05) in D-chronic rats, and even more so (44%, P < 0.05) in the ND:L- NAME-chronic rats despite the absence of hyperglycemia in the latter (Fig. 4) (11) and metabolic "pseudoischemia" (12) . Thus, neither temporal separation nor ARI sensitivity distinguish metabolic from vascular components of NCV slowing in experimental diabetic neuropathy.
Nitric oxide, with its increasingly appreciated functional diversity in cell metabolism, microvascular regulation, neuromodulation, and diabetes provides a strong theoretical bridge between AR2 and (Na+,K+)-ATPase and the vascular components of early experimental diabetic neuropathy. This study tested the hypothesis that impaired NO activity mediates the effect of increased AR2 activity on NCV and/or nerve (Na+,K+)-ATPase in the acutely STZ-D rat. The specific NOS inhibitor L-NAME completely blocked the salutary effects of a potent ARI on NCV in acute STZ-D rats, despite improvement in sorbitol accumulation and MI depletion; L-NAME alone had little effect on the already reduced NCV in acute STZ-D rats. These acute effects of L-NAME were prevented by arginine supplementation of the drinking water, consistent with its action as a competitive inhibitor of NOS (21) (22) (23) (24) . Chronic (12 wk) L-NAME administration to normal rats reproduced the NCV and (Na+,K+)-ATPase defects of chronic STZ-D, and, as anticipated, these were unaffected by ARI. Thus the ARI-sensitive slowing of NCV in acute STZ-D appears to be specific, and to some extent involve NO-related ischemic and/or metabolic (e.g., [Na+,K+]-ATPase) defects in nerve. (37) could modulate NOS by phosphorylation-dephosphorylation (38) .
The increased oxidative stress of diabetes (18, 21, 39) , attributed in part to increased local NADPH consumption by AR2 (11, 35) could inactivate NO through oxygen free radical formation (3), which could further impair vascular regulation in diabetes through the eicosanoid pathway (see below). Impaired endothelium-dependent vascular relaxation has been associated with experimental (15) (16) (17) and perhaps (40) human diabetes (41) , and attributed to NO depletion (15-18, 21, 39, 40, 42, 43) , NO resistance (44) and/or perturbation of vasoconstricting and vasodilating eicosanoids (45, 46) . The blunted endothelial-dependent vasodilatory response to acetylcholine (15, 16, 47) in the face of an intact endothelial-independent vasodilatory response to sodium nitroprusside (17) , nitroglycerin (16, 18) and other NO agonists implicates defective endothelial NO synthesis or release. This would in turn alter basal vascular tone through reduced activation of guanylate cyclase (17, 21, 48, 49) or perhaps (Na',K+)-ATPase in vascular smooth muscle (20) .
Nitric oxide deficiency might perturb NCV and nerve (Na+,K+)-ATPase through a nonischemic mechanism, perhaps interacting with other more well established AR2-related defects in signal transduction (1, (47) (48) (49) (50) (51) (52) (53) involved in modulation of (Na+,K+)-ATPase activity (1, 2, 9, 13, 54) . NO may modulate phosphoinositide turnover by unknown mechanisms (55) such that NO deficiency might act synergistically with MI depletion in altering phosphoinositide signal transduction and (Na+,K+)-ATPase regulation. The replication of a glucose-induced decrease in rabbit aortic (Na+,K+)-ATPase activity by a NOS inhibitor in vitro (20) supports this notion. Alternatively, the heightened ischemic sensitivity of neural (Na+,K+)-ATPase (56) , and the lack of vascular autoregulation in nerve (30) might predispose peripheral nerve (Na+,K+)-ATPase to NOrelated ischemia, possibly complicated by metabolic "pseudohypoxia" (12) .
The delayed effect of L-NAME vs STZ-D on NCV, and the failure of L-NAME to block the effects of dietary MI on NCV in STZ-D rats each deserve comment. Experimental diabetes predisposes nerve fibers to ischemic insult (57), perhaps reflecting defective compensatory vasoregulatory mechanisms such as the eicosanoid pathway (46) . A decrease in nerve prostacyclin in STZ-D has been speculated to favor vasoconstriction and thereby slow NCV (46, 58, 59) , which would explain the salutary effects of prostaglandin El analogues on NCV (13) possibly via nerve cyclic AMP (60) and/or (Na+,K+)-ATPase (54). Glucose-induced metabolic "pseudohypoxia" might also magnify NO-related ischemia in STZ-D rats, but not in L-NAME-treated nondiabetic rats (12) . Thus AR2-mediated NO depletion might initiate a complex cascade of ischemic and metabolic events that interact with other hyperglycemic/ischemic sequelae (12, 46, 61) to further compromise nerve blood flow and metabolism and degrade NCV in a self-reinforcing cycle. The delayed appearance of NCV slowing in L-NAMEtreated ND rats might simply reflect the absence of these other hyperglycemic sequelae.
The failure of L-NAME to counteract the salutary effects of MI feeding on NCV in STZ-D rats implies: (a) that ARIs correct NCV by a mechanism at least partially independent of MI repletion (12); (b) that MI feeding and ARI treatment correct MI depletion in a quantitatively or qualitatively different way; or (c) that NO itself mediates MI repletion by ARIs. Thus ARI therapy increases endoneurial blood flow (13) which might be prevented by L-NAME; nerve blood flow has not been well studied after MI feeding. Treatment with an ARI might improve (Na',K+)-ATPase function partly through a NO dependent vascular or metabolic mechanism, and partly via correction of MI and phosphoinositide metabolism (1). In contrast, MI feeding might work solely through the latter mechanism (2). Finally, ARI therapy and MI supplementation may restore NCV and/ or (Na',K+)-ATPase through entirely independent but parallel mechanisms. Thus the precise relationship between AR2 activation, MI depletion and NCV slowing in diabetes may be more complex than previously appreciated (1). In any case, the failure of L-NAME to slow NCV in MI-treated STZ-D rats despite persistent hypertension argues against a non-specific "neurotoxic" or hypertensive effect of L-NAME on NCV. (The lack of vascular autoregulation in nerve [30] causes nerve blood flow to fluctuate passively with blood pressure [62] such that increments in SBP would be expected to increase rather than decrease nerve blood flow.)
Although certain subtle complexities remain, these studies introduce NO as a potentially important mediator of AR2 effects on nerve (Na',K+)-ATPase and NCV in experimental diabetes. Even if the direct effect of NO on nerve (Na',K+)-ATPase reported in this study is not itself vascularly mediated (20) , the pivotal role of NO in microvascular regulation in general still serves to conceptually unify the so-called "vascular" and "metabolic" hypotheses for experimental diabetic neuropathy.
